Dermatology Xagena
Results from a phase 2b dose-ranging study of Dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema were presented. All ...
The results from the one-year phase 3 CHRONOS study have shown that patients receiving the investigational drug Dupilumab ( Dupixent ) with topical corticosteroids ( TCS ) achieved significantly impro ...
In the U.S.A., an Investigator's Global Assessment ( IGA ) score of less than or equal to 1 ( clear or almost clear skin ) has been the standard measure in regulatory outcomes for registration clinica ...
Dupilumab ( Dupixent ) is the first biologic available to treat atopic dermatitis. Its effectiveness and safety were demonstrated in clinical trials. The aim of study was to assess the effectivenes ...
